Difference between revisions of "Minutes - Medication WG 2021-05-25"
From Health Level 7 Belgium Wiki
KarlienErauw (talk | contribs) |
KarlienErauw (talk | contribs) |
||
| Line 1: | Line 1: | ||
===== '''Attendees''' ===== | ===== '''Attendees''' ===== | ||
| + | * Annemieke Vergauwe | ||
* Bruno Casneuf | * Bruno Casneuf | ||
| − | |||
* Elhassan Baazizi | * Elhassan Baazizi | ||
| − | * | + | * Jan Lenie |
| − | |||
* Jean-Michel Polfliet | * Jean-Michel Polfliet | ||
* Jens Penny | * Jens Penny | ||
* José Costa Teixeira | * José Costa Teixeira | ||
* Karlien Erauw | * Karlien Erauw | ||
| + | * Nick Hermans | ||
* Pablo Christiaens | * Pablo Christiaens | ||
| − | |||
* Robin Bosman | * Robin Bosman | ||
* Tom De Backer | * Tom De Backer | ||
* Tom Henkens | * Tom Henkens | ||
| − | |||
===== '''Excused/Not present''' ===== | ===== '''Excused/Not present''' ===== | ||
* Anne Nerenhausen | * Anne Nerenhausen | ||
| − | * | + | * Dieter Sauvillers |
| − | * | + | * Hanne Vuegen |
| + | * Jean-Louis Maggetto | ||
* Jeroen De Wilde | * Jeroen De Wilde | ||
* Lars Vanreppelen | * Lars Vanreppelen | ||
* Marc Buckens | * Marc Buckens | ||
* Nils Devos | * Nils Devos | ||
| − | + | * Richard Francken | |
| + | * Will van Norel | ||
===== '''Agenda''' ===== | ===== '''Agenda''' ===== | ||
| Line 31: | Line 31: | ||
===== '''Minutes''' ===== | ===== '''Minutes''' ===== | ||
* Magistral preparations: no update | * Magistral preparations: no update | ||
| + | * Pablo has sent useful feedback from the GP's | ||
| + | * ownership of the MS: can torpedize the project but is an important discussion and needs to be clarified. ownership needs to be defined: custodian, authorship, responsibility, ... | ||
| + | |||
| + | |||
| + | |||
* What is the purpose and intent of the high level modelling towards the scope of the medication scheme project and exchange of the related MS information, including the outcome | * What is the purpose and intent of the high level modelling towards the scope of the medication scheme project and exchange of the related MS information, including the outcome | ||
::* the purpose of the logical model is having a common understanding what the data means apart from the FHIR modelling | ::* the purpose of the logical model is having a common understanding what the data means apart from the FHIR modelling | ||
Revision as of 09:24, 25 May 2021
Attendees
- Annemieke Vergauwe
- Bruno Casneuf
- Elhassan Baazizi
- Jan Lenie
- Jean-Michel Polfliet
- Jens Penny
- José Costa Teixeira
- Karlien Erauw
- Nick Hermans
- Pablo Christiaens
- Robin Bosman
- Tom De Backer
- Tom Henkens
Excused/Not present
- Anne Nerenhausen
- Dieter Sauvillers
- Hanne Vuegen
- Jean-Louis Maggetto
- Jeroen De Wilde
- Lars Vanreppelen
- Marc Buckens
- Nils Devos
- Richard Francken
- Will van Norel
Agenda
- feedback on the model
Minutes
- Magistral preparations: no update
- Pablo has sent useful feedback from the GP's
- ownership of the MS: can torpedize the project but is an important discussion and needs to be clarified. ownership needs to be defined: custodian, authorship, responsibility, ...
- What is the purpose and intent of the high level modelling towards the scope of the medication scheme project and exchange of the related MS information, including the outcome
- the purpose of the logical model is having a common understanding what the data means apart from the FHIR modelling
- logical model is perceived as a flow
- What do we want to achieve here ? the MS, the careplan, ...
- the purpose is to achieve the MS
- are we going to translate kmehr to FHIR ? lots of risks
- starting from something completely new: we risk to lose data from the past, we need compatibility
- can the care plan be left out from this WG ?
- We miss the definition of the MS
- currently the MS in kmehr is visualised in a document
- MS can be the scheme for Vitalink
- there is a type/version
- What if an indication/treatment is confidential to one GP, one pharmacist will know of the dipsense of the medication without the indication, what about sharing to the vault
- will it be shared to the vault? mechanisms will have to be put in place
- permission resource will have to be added
- medication treatment vs medication summary vs medication scheme: there is a lack of detail in the modelling
- medication summary : sort of a view/snapshot on the medication
- medication scheme: digested scheme of a patient's medications
- kmehr MS with a concept of different medication treatments: what contains the list of medication treatment lines ? the medication treatment
- There is a need for examples and compilation to documents
- Therefore it would be useful to start a list with the examples that we need
- psychiatric medication with privacy settings
- medication having same substance used for different indications and different posologies
- distinction between hospital treatment and home therapy
- interactions between home therapy and psychiatric medication
- magistral preparations
- need to see clear example of and difference b/w treatments and summary
- Do we need support from pharmacist ?
- José will ask input from vidis
- Pablo will have a look
- Jens will try to provide input
- Tom H will check
Action items for next meeting
- each one of us to check offline and with his team to continue discussion on treatment lines
- status of approval of medication history : to provide by HL7 Belgium
Next meeting June 8 at 11AM
